Compare Microsoft (MSFT) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microsoft vs Sanofi SA — how do they compare? Microsoft trades at $396.87 (market cap $2.99T), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Microsoft is far larger — about 28.5× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| MSFT | SNY | |
|---|---|---|
Market Cap | $2.99T | $104.83B |
Volume | 36,654,621 | — |
Sector | Technology | Health |
52-Week High | $542.07 | $52.34 |
52-Week Low | $352.83 | $41.33 |
Enterprise Value | $2.97T | $121.32B |
Dividend Yield | 0.9% | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $397.75, up 1.0% today, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $281.72B in 2025, with net income of $101.83B, and the company has beaten EPS estimates for three consecutive quarters. Analysts maintain an 80.49% buy rating with a consensus price target of $546.70, highlighting AI leadership through Azure and Copilot.
The outlook remains positive given robust earnings growth and AI-driven opportunities, but risks include elevated capital expenditure concerns and competitive pressures. Valuation metrics like a P/E of 23.96 and P/S of 9.43 suggest the stock is fairly priced, supporting a long-term bullish view tempered by near-term volatility.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
